Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immune-mediated diseases. The company developing rilzabrutinib, an inhibitor that is in ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

Sandpoint's Bailey Lancaster recently committed to continue her softball career at Principia College (NCAA Division III) in ...

Principia and KIPP KC Legacy do battle in the MSHSAA Class 3 boys basketball final at 4 p.m. Thursday, March 13. / Jasen Vinlove-Imagn Images COLUMBIA, Mo. — Principia and KIPP KC Legacy will ...

Is Principia Biopharma Inc. (NASDAQ:PRNB) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it.

Sanofi’s Principia Biopharma is taking a one-two punch. Just days after one of the subsidiary's key BTK inhibitors crashed out of clinical testing, Sanofi has now disclosed it will wind down ...

PARIS – September 28, 2020 – Sanofi announced today the successful completion of its acquisition of Principia Biopharma Inc. (“Principia”) for $100 per share in cash. “The Principia acquisition ...

French pharmaceutical group Sanofi said on Monday, September 28, it has finalized acquisition of United States biotech firm Principia Biopharma for $3.7 billion. The operation, first announced in ...

The deal is summarized and Principia Biopharma’s Q2/20 clinical achievements are recapped in an H.C. Wainwright & Co. report. In an Aug. 17 research note, H.C. Wainwright & Co. analyst Joseph ...

The French drugmaker is buying American biotech Principia Biopharma for $3.7 billion, boosting its presence in the lucrative field of diseases in which the immune system attacks the body.